One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. - Wikidata - wikimedia - TriplyDB

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

http://www.wikidata.org/entity/Q34248537

about

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema Anti-vascular endothelial growth factor for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Updates on the Clinical Trials in Diabetic Macular Edema The clinical utility of aflibercept for diabetic macular edema Anti-VEGF Therapy and the Retina: An Update Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Endothelial progenitor cells in diabetic retinopathy Current trends in the monitoring and treatment of diabetic retinopathy in young adults Laser, intravitreal drug application, and surgery to treat diabetic eye disease Evaluation and management of patients with heart disease and cancer: cardio-oncology A review of anti-VEGF agents for proliferative diabetic retinopathy Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Prevalence of diabetic retinopathy among 13473 patients with diabetes mellitus in China: a cross-sectional epidemiological survey in six provinces Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Diabetic macular edema: New promising therapies.New Therapeutic Approaches in Diabetic Retinopathy.Cost-effectiveness of treatment of diabetic macular edema.Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards Bedside Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation Advances in diabetic retinopathy.Prevalence of and risk factors for diabetic macular edema in the United States.Pathophysiology and treatment of diabetic retinopathy.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Current treatments in diabetic macular oedema: systematic review and meta-analysis Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5).[VEGF inhibitors in vitreoretinal interventions].Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Ocular complications of diabetes mellitus.Anti-vascular endothelial growth factor therapy for diabetic macular edema Evolving strategies in the management of diabetic retinopathy Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema.Anti-VEGF for the management of diabetic macular edema.Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.Laser-based strategies to treat diabetic macular edema: history and new promising therapies.Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

P2860

Q24187587-E0060A41-97EF-4CCC-952F-F02C183A151D Q24193083-E582D9E5-9F80-4982-9E12-564A55422A33 Q24202071-97C12635-789B-4AD2-A1B5-3300C0221580 Q26767100-154D9633-5848-4098-A206-DC69FC64D35F Q26783575-89CD37F9-47AA-487C-B5FD-C25D23F5FACF Q26784605-A0328D8C-27A1-4598-BFB0-DB75F62CA08D Q26786012-D8C5FB1F-53C3-44E8-B550-98F7EA5B22FC Q26823985-94CE75F1-4979-4A40-83A9-FF5EE754252F Q26827206-F9F73912-802D-4EBC-AF3A-320CC82D0793 Q26863388-A653D8C4-1808-41C5-AE8D-E5653F241270 Q26995365-7E2D3C80-FE08-4954-9E71-06012FEB2CFB Q26998273-175FA36A-A0E0-4459-9C0D-358B96020CF9 Q27025643-C640EF75-00C8-43A8-8646-79F0FFE4FA44 Q28066675-8A061625-BEFA-40D1-A4D9-702676BE2E27 Q28075473-01A2C210-26D9-4B63-B7E2-C9FCF111AB8B Q28365372-35F5C658-56C9-4696-9C26-9CF61093F23C Q30101045-C9F0DE23-0744-4BAE-9981-432BB0AD2E0A Q30415630-537153A6-D0DF-4F38-8688-D99DA9429BD4 Q33583037-3D6AEFA1-C49D-4170-9366-7EF39EDD24C5 Q33606611-8CCAE40D-9CED-4B5B-88B9-AFC1D1BED54A Q33608021-B945930B-3E48-4CDC-A795-545959894A09 Q33910289-CF166CB8-1231-45E5-B0BE-C21A1A5A1E5B Q33956443-C5AEEAFA-E94E-456E-B14B-39A65B0D3ADC Q34319662-1DFADD5E-258B-4661-A2FD-06F570D3EA4A Q34433671-E2D34B9E-781F-41D5-B8DD-FE693331C932 Q34528134-884E19FC-687B-4038-A20D-DC46122AC1E3 Q34558187-068A8FB8-69D7-4514-A23B-13BEA2813826 Q34606190-AAA94299-8F07-4383-A1C1-5532C3F11E6F Q34758061-6B1C0D45-343D-4915-AEDB-DE07B19661C5 Q34792137-407E1317-359C-4545-A612-58B8547ED6DD Q34991648-0C833F1B-0DAF-499D-A112-1036F6587DA8 Q35016867-8EF332D4-A6B2-4BB0-BED1-53EB79D03233 Q35049903-D022D213-C8E5-426E-A8EA-4E1BC2FFE129 Q35064343-104B1219-D6CF-4575-9631-6C7542A7D502 Q35067102-4B2D89D8-02F8-418C-AB98-B0FFE3EA9C89 Q35083575-1556FB31-6090-4CA6-87BA-BCD2ED62AB7D Q35151008-5AC3F381-E8A0-4B57-B9AB-D29676E00BEA Q35173079-F40F3351-E811-4A8D-A158-D8A6F8BA29B7 Q35353446-8BD8E470-E1D5-48BC-B73F-C587A6D5C3C6 Q35575496-FB547D34-5B2B-41EC-83D3-7252FA7AD30E

P2860

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

http://www.wikidata.org/entity/Q34248537

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@ast

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@en

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@nl

type

label

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@ast

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@en

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@nl

prefLabel

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@ast

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@en

One-year outcomes of the da Vi ...... s with diabetic macular edema.

@nl

P1433

Q34248537-FEBB9065-1477-416C-AE2D-D79C6A8FF296

P1476

Q34248537-734F36EE-A2DD-407C-859B-0B898AFA0EF8

P2093

Q34248537-03AAD4B3-97B8-4D5C-9583-155BF1300D22

Q34248537-2BB4496C-1824-4008-873A-9B939D232E33

Q34248537-50981CA4-C74C-44FD-AF8A-BA115752009A

Q34248537-5D6DE794-D191-4127-8219-CC122C826663

Q34248537-69CFBD15-8C07-4CF6-A829-25C300CB00F6

Q34248537-8344EFDE-6F8C-4912-A0B7-122F68B9C90E

Q34248537-93F5E0C4-AD6D-43AE-98B0-0D7A06AB5EE5

Q34248537-B2BDBCD0-CBFE-4870-A2B3-A30A6D726EF9

Q34248537-B725E2F5-095D-4559-9D41-E75F6C0F0B2D

Q34248537-B95A4B99-BCBB-4C2E-90D0-629F9B879C9F

P304

Q34248537-07342194-6946-4651-A546-44269F7ABC22

P31

Q34248537-E7343E44-CF62-42F8-89BE-2585BCEA5928

P356

Q34248537-8C05BA90-B870-423B-8CEA-26A1C536D2A4

P433

Q34248537-A7F239DF-3DBE-487E-971B-C504DA5EA151

P478

Q34248537-30BCEAC8-1A01-4130-B30D-60C56073283F

P50

Q34248537-8361E413-2191-4F18-BD7A-B070413D6F13

P577

Q34248537-DC85BFC6-B173-4FC3-99CE-CFD8A1C9D60B

P5875

Q34248537-66033592-4723-449C-9D6E-20D4B20109C3

P698

Q34248537-C05EBCA5-BDEE-4931-993F-3F54372D0A80

P356

J.OPHTHA.2012.02.010

P1433

P1476

One-year outcomes of the da Vi ...... es with diabetic macular edema

@en

P2093

Alyson J Berliner

http://www.w3.org/2001/XMLSchema#string

Bo Gao

http://www.w3.org/2001/XMLSchema#string

David Boyer

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

Diana V Do

http://www.w3.org/2001/XMLSchema#string

Jeff S Heier

http://www.w3.org/2001/XMLSchema#string

Oliver Zeitz

http://www.w3.org/2001/XMLSchema#string

Quan Dong Nguyen

http://www.w3.org/2001/XMLSchema#string

Rene Ruckert

http://www.w3.org/2001/XMLSchema#string

Robert Vitti

http://www.w3.org/2001/XMLSchema#string

P304

1658-1665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2012.02.010

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Ursula Schmidt-Erfurth

P577

2012-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224853970

http://www.w3.org/2001/XMLSchema#string

P698

22537617

http://www.w3.org/2001/XMLSchema#string